{"id":"levalbuterol-udv-tid","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levalbuterol is the active R-enantiomer of albuterol that binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering intracellular signaling that increases cAMP levels and causes bronchodilation. The UDV (unit dose vial) formulation is administered via nebulizer three times daily (TID) for rapid onset of action in acute or maintenance therapy of asthma and COPD.","oneSentence":"Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:50.324Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance and acute bronchospasm relief"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT00685126","phase":"PHASE3","title":"Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-02","conditions":"Reactive Airways Disease (RAD)","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xopenex Inhalation Solution"],"phase":"phase_3","status":"active","brandName":"Levalbuterol UDV TID","genericName":"Levalbuterol UDV TID","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease. Used for Asthma maintenance and acute bronchospasm relief, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}